Through the creation of a computational platform that integrates multiple “omic” technologies, RARE Science can identify combinations of FDA-approved and promising therapeutics that address disease pathology. Our approach will enable the classification of disease by the underlying molecular etiologies which will allow consolidation of research efforts and leverage discovery in one disease across others of similar biology.
RARE Science will invest both directly and through its third party partners in continually expanding the understanding of disease. Funds raised for research in each particular disease will be applied to identifying therapeutic solutions for that disease. In addition, these efforts will be further leveraged by building out the research platform to broaden application to additional rare, neglected and orphan diseases.